Genetic background influences therapeutic effectiveness of VEGF
- 13 September 2003
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 310 (1) , 143-147
- https://doi.org/10.1016/j.bbrc.2003.08.134
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (15039213, 15390241, 15659180)
- Ministry of Health, Labour and Welfare
This publication has 21 references indexed in Scilit:
- A physical map of the mouse genomeNature, 2002
- Endothelial nitric oxide synthase is essential for the HMG‐CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemiaThe FASEB Journal, 2001
- Therapeutic Angiogenesis for Ischemic Cardiovascular DiseaseJournal of Molecular and Cellular Cardiology, 2001
- The Rise of the Mouse, Biomedicine's Model MammalScience, 2000
- Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1Science, 1999
- Impaired Collateral Vessel Development Associated With Reduced Expression of Vascular Endothelial Growth Factor in ApoE −/− MiceCirculation, 1999
- Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGFThe American Journal of Pathology, 1999
- Gene transfer into muscle by electroporation in vivoNature Biotechnology, 1998
- Vascular Endothelial Growth Factor Inhibits Endothelial Cell Apoptosis Induced by Tumor Necrosis Factor-α: Balance Between Growth and Death SignalsJournal of Molecular and Cellular Cardiology, 1997
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995